Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | PREP | P48147 | 1/20 | 0.37 |
| ▸ | FAP | Q12884 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25132417 | 0.98 | DPP4 (0.36) | DPP4PREPFAP | |
| SCHEMBL14669 | 0.84 | — | — | |
| SCHEMBL19774853 | 0.83 | DPP4 (0.34) | DPP4 | |
| SCHEMBL4546668 | 0.82 | DPP4 (0.39) | DPP4PREPFAP | |
| SCHEMBL25132889 | 0.82 | DPP4 (0.35) | DPP4PREPFAP | |
| SCHEMBL25129620 | 0.82 | DPP4 (0.35) | DPP4PREPFAP | |
| SCHEMBL25129436 | 0.81 | DPP4 (0.36) | DPP4PREPFAP | |
| SCHEMBL25129537 | 0.81 | DPP4 (0.36) | DPP4PREPFAP | |
| SCHEMBL25129493 | 0.81 | DPP4 (0.36) | DPP4PREPFAP | |
| SCHEMBL25129527 | 0.81 | DPP4 (0.36) | DPP4PREPFAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11739074-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2023-08-29 | — | — | US | disclosed |
| US-20210130326-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2021-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11739074-B2 | Ras inhibitors | KRAS, NRAS, HRAS | DPP4 3544/4885PREP 2469/4885FAP 304/4885 |
| US-20210130326-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | DPP4 2889/4885PREP 2672/4885FAP 272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.